Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CANF Can-Fite BioPharma	$1.04 -5.0%	$1.35	$0.98 ▼ $4.69	$3.66M	1.18	238,564 shs	228,421 shs
LPTX Leap Therapeutics	$0.41 +2.3%	$0.37	$0.22 ▼ $4.79	$16.95M	-0.17	831,243 shs	258,011 shs
UBX Unity Biotechnology	$0.75 -8.0%	$1.15	$0.70 ▼ $3.10	$12.82M	1.28	125,581 shs	214,258 shs
UPXI Upexi	$9.78 -2.3%	$5.54	$1.90 ▼ $22.57	$13.95M	-0.27	847,159 shs	187,280 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CANF Can-Fite BioPharma	-5.05%	-5.91%	-20.38%	-31.46%	-51.41%
LPTX Leap Therapeutics	+2.25%	+19.24%	+19.94%	-19.49%	-85.13%
UBX Unity Biotechnology	-8.02%	-16.85%	-23.20%	-62.37%	-51.31%
UPXI Upexi	-2.30%	-14.88%	+262.22%	+144.50%	+22.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CANF Can-Fite BioPharma	1.4617 of 5 stars	3.7	0.0	0.0	0.0	0.0	1.3
LPTX Leap Therapeutics	2.2311 of 5 stars	3.1	4.0	0.0	2.0	0.0	1.3
UBX Unity Biotechnology	4.4464 of 5 stars	3.5	3.0	4.7	3.9	0.8	1.3
UPXI Upexi	0.9321 of 5 stars	0.0	2.0	0.0	3.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CANF Can-Fite BioPharma	3.33	Buy	$14.00	1,252.66% Upside
LPTX Leap Therapeutics	2.25	Hold	$4.92	1,102.12% Upside
UBX Unity Biotechnology	3.00	Buy	$5.33	615.88% Upside
UPXI Upexi	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CANF, LPTX, UBX, and UPXI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/23/2025	UBX Unity Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/23/2025	UBX Unity Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/15/2025	CANF Can-Fite BioPharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/27/2025	LPTX Leap Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/25/2025	UBX Unity Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
3/24/2025	UBX Unity Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
3/18/2025	CANF Can-Fite BioPharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/10/2025	UBX Unity Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/10/2025	UBX Unity Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/3/2025	CANF Can-Fite BioPharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
2/18/2025	CANF Can-Fite BioPharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CANF Can-Fite BioPharma	$674K	5.44	N/A	N/A	$1.76 per share	0.59
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$2.35 per share	N/A
UBX Unity Biotechnology	$240K	53.43	N/A	N/A	$1.69 per share	0.44
UPXI Upexi	$18.63M	0.75	N/A	N/A	$2.85 per share	3.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CANF Can-Fite BioPharma	-$7.63M	-$1.79	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	-$81.41M	-$1.84	N/A	N/A	N/A	N/A	-116.24%	-93.18%	N/A
UBX Unity Biotechnology	-$39.86M	-$1.62	N/A	N/A	N/A	N/A	-119.70%	-45.86%	N/A
UPXI Upexi	-$23.66M	N/A	0.00	∞	N/A	N/A	N/A	N/A	7/8/2025 (Estimated)

Latest CANF, LPTX, UBX, and UPXI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	LPTX Leap Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	N/A	N/A
4/22/2025	Q1 2025	UBX Unity Biotechnology	-$0.43	-$0.43	N/A	-$0.43	N/A	N/A
3/26/2025	Q4 2024	LPTX Leap Therapeutics	-$0.39	-$0.37	+$0.02	-$0.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CANF Can-Fite BioPharma	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A
UBX Unity Biotechnology	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CANF Can-Fite BioPharma	N/A	2.93	N/A
LPTX Leap Therapeutics	N/A	3.97	3.97
UBX Unity Biotechnology	N/A	3.45	3.45
UPXI Upexi	0.35	0.58	0.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CANF Can-Fite BioPharma	21.00%
LPTX Leap Therapeutics	30.46%
UBX Unity Biotechnology	29.49%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
CANF Can-Fite BioPharma	0.80%
LPTX Leap Therapeutics	5.40%
UBX Unity Biotechnology	5.80%
UPXI Upexi	34.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CANF Can-Fite BioPharma	8	3.54 million	N/A	Not Optionable
LPTX Leap Therapeutics	40	41.44 million	36.25 million	Optionable
UBX Unity Biotechnology	60	17.21 million	15.87 million	Optionable
UPXI Upexi	130	1.43 million	863,000	Optionable

CANF, LPTX, UBX, and UPXI Headlines

Recent News About These Companies

Upexi Buys Discounted Locked SOL, Surpasses $100 Million of SOL and Becomes the Largest Publicly-Traded Solana Treasury Company

May 12 at 8:17 AM | finanznachrichten.de

Upexi Increases Solana Treasury to 201,500 Solana Tokens for $30 Million and Begins to Generate Staking Revenue

May 6, 2025 | finanznachrichten.de

Classover Bets On Solana To Reshape Its Balance Sheet, Financial Strategy – Stock Continues Rally With 70% Pre-Market Jump

May 2, 2025 | msn.com

This is Why Companies are Diversifying with Cryptocurrencies, Like Bitcoin

April 30, 2025 | baystreet.ca

CORRECTION FROM SOURCE: Upexi Purchases 45,733 Solana Tokens as it Begins Deploying $100 Million Treasury in Solana Strategy

April 29, 2025 | finanznachrichten.de

Upexi Purchases 45,733 Solana Tokens as it Begins Deploying $100 Million Treasury in Solana Strategy

April 29, 2025 | finance.yahoo.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) CFO Purchases 43,860 Shares of Stock

April 26, 2025 | insidertrades.com

SOL Strategies Channels MicroStrategy With $500M Solana Play—Is Solaxy The Real Winner?

April 25, 2025 | insidebitcoins.com

Upexi Announces Closing of $100 Million Private Placement

April 24, 2025 | accessnewswire.com

Upexi Stock Surges 630% Following $100M Solana Treasury Announcement

April 22, 2025 | blockonomi.com

Solana Soars 8% On Institutional Bets As Layer-2 Solaxy Emerges As Future SOL Backbone

April 22, 2025 | insidebitcoins.com

Why Upexi, Inc. (UPXI) Soared on Monday

April 22, 2025 | insidermonkey.com

Upexi turns to Solana for Treasury strategy in $100 million deal with GSR

April 22, 2025 | fxstreet.com

GSR Anchors $100M Investment in Upexi to Purchase SOL, Stock Rockets 700%

April 21, 2025 | finance.yahoo.com

Upexi Says It Is Raising $100 Million to Buy Solana Crypto Token

April 21, 2025 | bloomberg.com

Upexi prices 43.86M shares at $2.28 in private placement

April 21, 2025 | markets.businessinsider.com

Crypto Stock Upexi, Inc. (NASDAQ:UPXI) Makes NASDAQ Top Percentage Gainer

April 21, 2025 | investorideas.com

Nasdaq-listed Upexi shares up 630% after $100M raise, SOL treasury

April 21, 2025 | msn.com

Upexi Stock Soars Over 600% On $100M Solana Treasury Bet

April 21, 2025 | msn.com

GSR Leads $100M Private Placement into Nasdaq-listed Upexi, Inc. to Back Solana-Based Treasury Strategy

April 21, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CANF, LPTX, UBX, and UPXI Company Descriptions

Can-Fite BioPharma NYSE:CANF

$1.03 -0.06 (-5.05%)

As of 05/14/2025 03:59 PM Eastern

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Leap Therapeutics NASDAQ:LPTX

$0.41 +0.01 (+2.25%)

As of 05/14/2025 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Unity Biotechnology NASDAQ:UBX

$0.74 -0.07 (-8.02%)

As of 05/14/2025 04:00 PM Eastern

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Upexi NASDAQ:UPXI

$9.78 -0.23 (-2.30%)

As of 05/14/2025 04:00 PM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time